Your browser doesn't support javascript.
loading
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis.
Triaille, Clément; Quartier, Pierre; De Somer, Lien; Durez, Patrick; Lauwerys, Bernard R; Verschueren, Patrick; Taylor, Peter C; Wouters, Carine.
Afiliación
  • Triaille C; Pôle de Pathologies Rhumatismales Systémiques et Inflammatoires, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
  • Quartier P; Department of Pediatric Hematology, Oncology, Immunology and Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • De Somer L; Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
  • Durez P; Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
  • Lauwerys BR; Université Paris-Cité, Paris, France.
  • Verschueren P; Member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases - Project ID No. 739543.
  • Taylor PC; Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
  • Wouters C; Member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases - Project ID No. 739543.
Rheumatology (Oxford) ; 63(3): 594-607, 2024 Mar 01.
Article en En | MEDLINE | ID: mdl-37725352
Biologic and targeted synthetic DMARDs (b/tsDMARDs) have revolutionized the management of multiple rheumatic inflammatory conditions. Among these, polyarticular JIA (pJIA) and RA display similarities in terms of disease pathophysiology and response pattern to b/tsDMARDs. Indeed, the therapeutic efficacy of novel targeted drugs is variable among individual patients, in both RA and pJIA. The mechanisms and determinants of this heterogeneous response are diverse and complex, such that the development of true 'precision'-medicine strategies has proven highly challenging. In this review, we will discuss pathophysiological, patient-specific, drug-specific and environmental factors contributing to individual therapeutic response in pJIA in comparison with what is known in RA. Although some biomarkers have been identified that stratify with respect to the likelihood of either therapeutic response or non-response, few have proved useful in clinical practice so far, likely due to the complexity of treatment-response mechanisms. Consequently, we propose a pragmatic, patient-centred and clinically based approach, i.e. personalized instead of biomarker-based precision medicine in JIA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis / Antirreumáticos Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis / Antirreumáticos Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Reino Unido